<?xml version="1.0" encoding="UTF-8"?>
<p id="par0085">The administration of influenza vaccines is recommended to prevent virus infection. During 2017â€“2018, the influenza vaccination prevented 91,000 influenza-related hospitalizations [
 <xref rid="bib0135" ref-type="bibr">27</xref>]. The current influenza vaccine induces a prophylactic antibody response against the HA and NA proteins. The preventive vaccines in the market include Trivalent inactivated influenza (TRI) and quadrivalent live attenuated influenza viruses (LAIV), such as FluMist and Fluzone. New variants of the virus emerge constantly, therefore, the type of vaccine preparation must be predicted and generated before strain identification for the upcoming year. It is often challenging to predict epidemics due to the high diversity of viral subtypes [
 <xref rid="bib0145" ref-type="bibr">29</xref>]. Next, we summarize a few peptide-based vaccines that have reached the advanced stages of clinical trials.
</p>
